全文获取类型
收费全文 | 854篇 |
免费 | 27篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 18篇 |
妇产科学 | 9篇 |
基础医学 | 227篇 |
口腔科学 | 13篇 |
临床医学 | 58篇 |
内科学 | 177篇 |
皮肤病学 | 19篇 |
神经病学 | 19篇 |
特种医学 | 12篇 |
外国民族医学 | 2篇 |
外科学 | 24篇 |
综合类 | 61篇 |
预防医学 | 31篇 |
眼科学 | 4篇 |
药学 | 88篇 |
中国医学 | 17篇 |
肿瘤学 | 127篇 |
出版年
2024年 | 1篇 |
2023年 | 10篇 |
2022年 | 7篇 |
2021年 | 18篇 |
2020年 | 13篇 |
2019年 | 18篇 |
2018年 | 13篇 |
2017年 | 13篇 |
2016年 | 12篇 |
2015年 | 16篇 |
2014年 | 19篇 |
2013年 | 62篇 |
2012年 | 26篇 |
2011年 | 47篇 |
2010年 | 28篇 |
2009年 | 34篇 |
2008年 | 36篇 |
2007年 | 48篇 |
2006年 | 34篇 |
2005年 | 30篇 |
2004年 | 44篇 |
2003年 | 33篇 |
2002年 | 21篇 |
2001年 | 31篇 |
2000年 | 33篇 |
1999年 | 35篇 |
1998年 | 28篇 |
1997年 | 35篇 |
1996年 | 32篇 |
1995年 | 33篇 |
1994年 | 26篇 |
1993年 | 17篇 |
1992年 | 14篇 |
1991年 | 19篇 |
1990年 | 11篇 |
1989年 | 7篇 |
1988年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
排序方式: 共有907条查询结果,搜索用时 468 毫秒
11.
GM-CSF对MUC1基因疫苗抑制乳腺癌生长的增强作用 总被引:5,自引:2,他引:5
目的 :观察GM CSF有无增强MUC1基因疫苗对EMT6乳腺癌生长的特异性抑制作用。方法 :采用股四头肌肌肉注射法 ,将构建的MUC1基因疫苗pcDNA3.1 MUC1免疫雌性BALB/c小鼠 ,每 3wk 1次 ,共 3次。每次基因免疫后 1、3、5d ,皮下注射GM CSF 10 0 μL(1μg/ 10 0 μL)。最后 1次基因免疫后第 3周 ,接种表达MUC1的EMT6小鼠乳腺癌细胞。两周后观察、记录肿瘤的生长情况。于肿瘤细胞接种后第 4 3天 ,处死全部动物 ,称量肿瘤的质量。用 4h51Cr释放法检测小鼠脾特异性CTL的杀伤活性。结果 :接种肿瘤细胞后 4 3d ,MUC1基因疫苗加GM CSF组、MUC1基因疫苗组、pcDNA3.1加GM CSF组及pcDNA3.1组 ,EMT6肿瘤的大小依次为 (135± 33.8)mm3 、(2 5 0± 34.3)mm3 、(5 6 8± 4 3.6 )mm3 和 (5 96± 4 8.2 )mm3 ;平均瘤质量 (g)依次为 (0 .81± 0 .4 2 )g、(1.2 3± 0 .4 1)g、(2 .30± 0 .4 8)g及 (2 .2 8± 0 .5 8)g。与对照组相比较 ,MUC1基因疫苗组EMT6肿瘤的生长受到明显抑制 (P <0 .0 5 ) ;与单独MUC1基因疫苗组相比较 ,MUC1基因疫苗加GM CSF组抗肿瘤生长的作用有显著差异 (P <0 .0 5 )。在效靶比为 10 0∶1、5 0∶1、2 5∶1和 12 .5∶1时 ,MUC1基因疫苗加GM CSF组特异性CTL对EMT6靶细胞的杀伤率 ,依次为 6 8.5 %、 5 3.4 % 相似文献
12.
An interleukin-3-dependent progenitor clone LyD9 and its interleukin-4-dependent derivative clone K-4 were shown to differentiate into myeloid cells as well as B lymphocytes by coculture with bone marrow stroma cells. The K-4 clone is an intermediate between myeloid/lymphoid cells and the LyD9 clone that requires interleukin-4 for differentiation into B lymphocytes and myeloid cells. Granulocyte-macrophage colony stimulating factor-dependent derivatives (LS-1 and K-GM) were also established from induced LyD9 cells. LS-1 and K-GM were myeloid-committed cells. 相似文献
13.
Stefanie Kreutmair Susanne Unger Nicolás Gonzalo Núñez Florian Ingelfinger Chiara Alberti Donatella De Feo Sinduya Krishnarajah Manuel Kauffmann Ekaterina Friebel Sepideh Babaei Benjamin Gaborit Mirjam Lutz Nicole Puertas Jurado Nisar P. Malek Siri Goepel Peter Rosenberger Helene A. Häberle Ikram Ayoub Burkhard Becher 《Immunity》2021,54(7):1578-1593.e5
14.
15.
目的 应用细胞培养技术检测了墓头回水提物对人脐血基质细胞生成及其分泌粒系造血刺激因子的实验研究。方法 将不同浓度的墓头回水提物与脐血共同培养14d,检测基质细胞上清液中的GM-CSF活性。结果 墓头回水提物对人脐血基质细胞具有促进形成的作用,最高峰为0.01μg/mL,为了检测基质细胞上清液中的GM-CSF活性,进行了GM-CFU实验,结果表明,实验各组数据与对照组比较,具有非常显著性差异(P<0.01)。结论 墓头回水提物不仅是一种强烈的抗癌药物,也是一种造血祖细胞促进剂。 相似文献
16.
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant 总被引:5,自引:0,他引:5
McNeel DG Knutson KL Schiffman K Davis DR Caron D Disis ML 《Journal of clinical immunology》2003,23(1):62-72
A pilot vaccine study was conducted to test the safety and immunological efficacy of four monthly immunizations of an MHC class I peptide vaccine, the E75 HLA-A2 epitope from HER-2/neu, using flt3 ligand as a systemic vaccine adjuvant. Twenty HLA-A2-expressing subjects with advanced stage prostate cancer were randomly assigned to one of four immunization or treatment schedules: (a) Flt3 ligand (20 g/kg per day) administered subcutaneously daily for 14 days on a 28-day cycle, monthly for four months; (b) flt3 ligand course as above with the E75 peptide vaccine administered on day 7 of each flt3 ligand cycle; (c) flt3 ligand course as above with the E75 peptide vaccine administered on day 14 of each flt3 ligand cycle; or (d) E75 peptide admixed with granulocyte–macrophage colony-stimulating factor and administered intradermally once every 28 days, as has previously been reported. The primary endpoints of the study were the determination of safety and immunological efficacy in generating E75-specific T cells as determined by peptide-specific interferon-gamma ELIspot. Adverse events included one grade 3 skin reaction and the development of grade 2 autoimmune hypothyroidism in two subjects with preexisting subclinical autoimmune hypothyroidism. Dendritic cells were markedly increased in the peripheral blood of subjects receiving flt3 ligand with each repetitive cycle, but augmentation of antigen-presenting cells within the dermis was not observed. Apart from a single subject, no significant peptide-specific T-cell responses were detected by ELIspot, whereas delayed-type hypersensitivity responses were detectable in control subjects and in subjects receiving peptide vaccine early in the course of flt3 ligand administration. The absence of robust peripheral immune responses in the current study may be attributable to the small numbers of subjects or differences in the subject population. In addition, the inability of flt3 ligand to augment the number of peripheral skin antigen-presenting cells may have contributed to the absence of robust peptide-specific immunity detectable in the peripheral blood of immunized subjects treated with flt3 ligand. 相似文献
17.
18.
Shimpei Ariki Sotaro Ozaka Nozomi Sachi Thanyakorn Chalalai Yasuhiro Soga Chiaki Fukuda Yomei Kagoshima Supanuch Ekronarongchai Kazuhiro Mizukami Naganori Kamiyama Kazunari Murakami Takashi Kobayashi 《Genes to cells : devoted to molecular & cellular mechanisms》2023,28(4):267-276
Although excessive immune responses by Th17 cells, a helper T cell subset, are implicated in the pathogenesis of inflammatory bowel disease (IBD), the mechanism by which its localization in an inflamed colon is regulated remains unclear. Chemokines and their receptors are involved in the pathogenesis of IBD, however, the relative significance of each receptor on Th17 cells remains unknown. We generated C–C motif chemokine receptor 2 (CCR2) knockout (KO) and CCR6 KO mice in the syngeneic background using the CRISPR/Cas9 system and found that the phenotypes of experimental colitis worsened in both mutant mice. Surprisingly, the phenotype of colitis in CCR2/CCR6-double knockout (CCR2/6 DKO) mice was opposite to that of the single-deficient mice, with significantly milder experimental colitis (p < .05). The same was true for the symptoms in CCR6 KO mice, but not in wild type mice treated with a CCR2 inhibitor, propagermanium. Colonic CCR2+CCR6+ Th17 cells produced a potentially pathogenic cytokine GM-CSF whose levels in the gut were significantly reduced in CCR2/6 DKO mice (p < .05). These results suggest that GM-CSF-producing CCR2+CCR6+ Th17 cells are pathogenic and are attracted to the inflamed colon by either CCR2 or CCR6 gradient, which subsequently exacerbates experimental colitis in mice. 相似文献
19.
mGM-CSF重组质粒的构建、表达及活性鉴定 总被引:3,自引:0,他引:3
目的 构建pc—mGM—CSF重组质粒载体,为mGM—CSF基因治疗肿瘤的研究奠定基础。方法 采用RT—PCR方法从小鼠脾脏中获得目的基因mGM—CSF,克隆于pcDNA3.1/Myc-His(-)(A)质粒上,成为pc-mGM-CSF,用PCR、酶切进行鉴定,然后用脂质体转染小鼠骨髓瘤细胞SP2/0,用G418筛选后通过RT—PCR和SDS—PAGE鉴定,将转染SP2/0上清加入NFS-60细胞,检测蛋白活性。结果 重组质粒中含有mGM—CSF基因,在SP2/0中有表达,且表达产物能分泌到肿瘤细胞外,分泌到细胞外的产物用mGM—CSF依赖株NFS-60细胞检测证明具有生物学活性。结论 成功构建含mGM—CSF真核表达重组质粒,有助于进一步研究其抗肿瘤作用。 相似文献
20.
C Dazzi A Cariello P Giovanis M Monti B Vertogen M Leoni A Tienghi D Turci G Rosti O Nanni C Rondoni M Marangolo 《Annals of oncology》2003,14(4):559-563
BACKGROUND: The aim of this study was to evaluate the effectiveness of granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwashes in the prevention of severe mucositis induced by high doses of chemotherapy. PATIENTS AND METHODS: Ninety consecutive patients affected by solid tumors and undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue were randomized to receive placebo versus GM-CSF mouthwash 150 micro g/day. Patients were stratified on the basis of the conditioning treatment and the consequent different risk of severe oral mucositis. Treatment was administered from the day after the end of chemotherapy until the resolution of stomatitis and/or neutrophil recovery. RESULTS: The statistical analyses were intention-to-treat and involved all patients who entered the study. The severity of stomatitis was evaluated daily by the physicians according to National Cancer Institute Common Toxicity Criteria. Both study and control groups were compared with respect to the frequency [30% versus 36%, chi(2) exact test, not significant (NS)] and mean duration (4.8 +/- 4.7 versus 4.4 +/- 2.7 days, t-test, NS) of severe stomatitis (grade > or =3). Oral pain was evaluated daily by patients themselves by means of a 10 cm analog visual scale: the mean (+/- standard error of the mean) maximum mucositis scores were 4.8 +/- 3.5 versus 4.2 +/- 3.5 cm (t-test, NS). Furthermore, 15/46 patients in the study group (33%) and 19/44 patients in the control group experienced pain requiring opioids (chi(2) exact test, NS). CONCLUSION: We did not find any evidence to indicate that prophylaxis with GM-CSF mouthwash can help to reduce the severity of mucositis in the setting of the patients we studied. 相似文献